DOS [Dosing Optimization Study]: Open-label, Single-arm, Proof-of-Concept Dosing Study of Afrezza® in Adult Subjects 18 Years and Older With Type 1 or Type 2 Diabetes Mellitus
Mannkind Corporation's Afrezza is positioned in the competitive landscape of diabetes management, particularly for patients with Type 1 and Type 2 diabetes. The Dosing Optimization Study (MKC-TI-191) aims to enhance the understanding of Afrezza's efficacy in conjunction with basal insulin, potentially improving patient adherence and glycemic control. The results could strengthen Afrezza's market positioning against traditional insulin therapies and other inhaled insulin products. The study's completion and subsequent data may attract interest from healthcare providers and payers, influencing market uptake and reimbursement strategies.
Indication: Diabetes Mellitus, Type 1
Modality: combination therapy
Target: Inhaled insulin delivery via Technosphere technology.
Sponsor: Mannkind Corporation
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Inhaled insulin delivery via Technosphere technology.
View original source fields
Condition raw: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Condition normalized: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Inhaled insulin delivery via Technosphere technology.
Target normalized: Inhaled insulin delivery via Technosphere technology.